Home-Nebulized Inhaled Glucocorticoid Therapy in Pediatric Respiratory Diseases

Abstract

Objective: To evaluate the therapeutic effect of home-nebulized inhaled glucocorticoid therapy in pediatric respiratory diseases. Methods: 60 cases of children with respiratory diseases admitted between October 2022 and October 2023 were selected as study subjects and randomly divided into the control group and the observation group, 30 cases each. The control group was provided with conventional treatment only, while the observation group was provided with home-nebulized inhalation glucocorticosteroid treatment, and the treatment effects, clinical symptom relief time, disease recurrence rate, and treatment satisfaction of the children’s families were recorded and compared between the two groups. Results: A comparison of the two groups in terms of gender and age showed that the differences were not statistically significant (P > 0.05). In terms of clinical efficacy, the total effective rate of the observation group was 90.00%, which was significantly higher than that of the control group of 66.67% (P < 0.05). Compared with the control group, the disappearance time of the clinical symptoms of the observed group was significantly shortened (P < 0.05). In addition, the satisfaction scores of the families of the children in the observation group were significantly higher than those of the control group (P < 0.05). Conclusion: Home-nebulized inhalation glucocorticoid therapy shows significant clinical efficacy in pediatric respiratory diseases, significantly reduces the time of disappearance of clinical symptoms, and improves the satisfaction of patients’ families, which provides an effective treatment option for children.